Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
New York, NY
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Birmingham, AL
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Fort Smith, AR
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Aurora, CO
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Decatur, GA
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Overland Park, KA
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Louisville, KY
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Metairie, LA
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Baltimore, MD
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Boston, MA
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Omaha, NE
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
New York, NY
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Bismarck, ND
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Cleveland, OH
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Tulsa, OK
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Portland, OR
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Dallas, TX
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Norfolk, VA
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Seattle, WA
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated:  10/15/2012
Clinical Research Facility
mi
from
Huntington, WV
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
Status: Enrolling
Updated: 10/15/2012
Clinical Research Facility
mi
from
Huntington, WV
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Sites 37, 50, Birmingham Pediatric Associates, 806 Saint Vincent's Drive, Suite 615
mi
from
Birmingham, AL
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Sites 37, 50, Birmingham Pediatric Associates, 806 Saint Vincent's Drive, Suite 615
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 6, Kaiser Permanente Fremont, 39400 Paseo Padre Parkway
mi
from
Fremont, CA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 6, Kaiser Permanente Fremont, 39400 Paseo Padre Parkway
mi
from
Fremont, CA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 7, Kaiser Permanente Fresno, 4785 North First Street, 3rd Floor
mi
from
Fresno, CA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 7, Kaiser Permanente Fresno, 4785 North First Street, 3rd Floor
mi
from
Fresno, CA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 8, Kaiser Permanente Hayward, 27303 Sleepy Hollow Ave., 1st Floor, MOB
mi
from
Hayward, CA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 8, Kaiser Permanente Hayward, 27303 Sleepy Hollow Ave., 1st Floor, MOB
mi
from
Hayward, CA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 9, Kaiser Permanente Roseville, 1840 Sierra Gardens Drive, Vaccine Studies
mi
from
Roseville, CA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 9, Kaiser Permanente Roseville, 1840 Sierra Gardens Drive, Vaccine Studies
mi
from
Roseville, CA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 11, Kaiser Permanente Sacramento, 6600 Bruceville Rd., Pediatric Station C
mi
from
Sacramento, CA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 11, Kaiser Permanente Sacramento, 6600 Bruceville Rd., Pediatric Station C
mi
from
Sacramento, CA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 10, Kaiser Permanente San Jose, 276 International Circle, Family Health Center, Unit B1
mi
from
San Jose, CA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 10, Kaiser Permanente San Jose, 276 International Circle, Family Health Center, Unit B1
mi
from
San Jose, CA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 2, PAMPA, 2155 Post Oak Tritt Road, Suite 100
mi
from
Marietta, GA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 2, PAMPA, 2155 Post Oak Tritt Road, Suite 100
mi
from
Marietta, GA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 3, PAMPA, 120 Stonebridge Parkway Ste. 410
mi
from
Woodstock, GA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 3, PAMPA, 120 Stonebridge Parkway Ste. 410
mi
from
Woodstock, GA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 53, Pediatric/Adult Research Inc., 201 South Fifth Street, Suite 102
mi
from
Bardstown, KY
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 53, Pediatric/Adult Research Inc., 201 South Fifth Street, Suite 102
mi
from
Bardstown, KY
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 38, Akron Children's Hospital, One Perkins Square
mi
from
Akron, OH
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 38, Akron Children's Hospital, One Perkins Square
mi
from
Akron, OH
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 43, Dr. Senders and Associates, 2054 South Green Road
mi
from
South Euclid, OH
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 43, Dr. Senders and Associates, 2054 South Green Road
mi
from
South Euclid, OH
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 35, Pennridge Pediatric Associates, 711 Lawn Avenue
mi
from
Sellersville, PA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 35, Pennridge Pediatric Associates, 711 Lawn Avenue
mi
from
Sellersville, PA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 60, Peak Research, 2589 Washington Road, Suite 412B
mi
from
Upper St. Clair, PA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 60, Peak Research, 2589 Washington Road, Suite 412B
mi
from
Upper St. Clair, PA
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 47, UTMB Galveston Office of Pediatric Clinical Trials Children's Hospital, 301 University Blvd., Rm 1 288H
mi
from
Galveston, TX
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 47, UTMB Galveston Office of Pediatric Clinical Trials Children's Hospital, 301 University Blvd., Rm 1 288H
mi
from
Galveston, TX
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 56, J. Lewis Research, Inc/Foothill Family Clinic South, 2295 Foothill Drive
mi
from
Salt Lake City, UT
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 56, J. Lewis Research, Inc/Foothill Family Clinic South, 2295 Foothill Drive
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  10/16/2012
Site 45, Group Health Research Institute, 1730 Minor Ave, Suite 1600
mi
from
Seattle, WA
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
An Open-Label, Multi-Center Study to Evaluate the Persistence Of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercial Available MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 10/16/2012
Site 45, Group Health Research Institute, 1730 Minor Ave, Suite 1600
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% for the Treatment of Acute Otitis Externa
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Status: Enrolling
Updated:  10/16/2012
Call Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% for the Treatment of Acute Otitis Externa
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Status: Enrolling
Updated: 10/16/2012
Call Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction
Status: Enrolling
Updated:  10/16/2012
Clinical Pharmacology of Miami
mi
from
Miami, FL
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction
Status: Enrolling
Updated: 10/16/2012
Clinical Pharmacology of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction
Status: Enrolling
Updated:  10/16/2012
Orlando Clinical Research Center
mi
from
Orlando, FL
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction
Status: Enrolling
Updated: 10/16/2012
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction
Status: Enrolling
Updated:  10/16/2012
New Orleans Center for Clinical Research - Knoxville
mi
from
Knoxville, TN
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction
Status: Enrolling
Updated: 10/16/2012
New Orleans Center for Clinical Research - Knoxville
mi
from
Knoxville, TN
Click here to add this to my saved trials
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
Predictive Modeling of Anal Dysplasia Progression in HIV
Status: Enrolling
Updated:  10/16/2012
Cincinnati VA Medical Center
mi
from
Cincinnati, OH
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
Predictive Modeling of Anal Dysplasia Progression in HIV
Status: Enrolling
Updated: 10/16/2012
Cincinnati VA Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials